EN DE
Watch Malaysian Genomics Resource for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Malaysian Genomics Resource (0155) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Malaysian Genomics Resource stock MYR 0.17, price MYR 0.31, that is 44.3% below the price, quality 69 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare MY · ISIN MYQ0155OO000

MG Malaysian Genomics Resource logo Thin data Nov 4, 2026

Malaysian Genomics Resource

0155 · KLSE
Solid, but very expensive

Our calculation puts a fair price 44% below what the stock costs today.

Quality 69/100
Low debt
Generates free cash flow
Revenue last quarter +42% vs. a year ago.
Mixed Growth (revenue 5y +35.1 %/yr in MYR)
Thin margins · 5.3% net margin (TTM)
Fair value 0.1700 MYR · Strongly overvalued
Trails peers (4/12)
Narrow moat 32/100 · thin data
Thin data
Watch Malaysian Genomics Resource for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

2.72 MYR 0.1450 MYR Fair Value 0.1700 MYR Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 0.1450 MYR – 2.72 MYR · fair‑value band 0.0900 MYR – 0.2600 MYR · the 0.3050 MYR price screens above the 0.1700 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Malaysian Genomics Resource in your weekly email

Every Wednesday you see whether Malaysian Genomics Resource is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services in Malaysia.

Show moreShow less

The company offers genetic screening services that includes Dtect and Origene genetic testing solutions which provides individuals with insights into genetic predispositions related to health risks, wellness, and lifestyle traits.

It also provides immunotherapy and cell therapy which offers mesenchymal stem cells derived from ethically sourced human umbilical cords, as well as natural killer cell therapies designed to strengthen the body's immune response that are relevant in the treatment of cancers, autoimmune diseases, and other complex conditions.

In addition, the company offers genome sequencing and bioinformatics services; personalized supplements; cellular therapy for regenerative health; and cell-free therapy for regeneration and repair.

Further, it is involved in dealing in capital markets and derivative instruments; acting as general merchants; research, development, and commercialization of biopharmaceutical products and services; business relating to life sciences/cell lab and by products; and distribution of healthcare products, beauty products, and precision medicine.

Additionally, the company provides system developments and information technology comprising software and hardware, as well as other human health services and general medical services. Malaysian Genomics Resource Centre Berhad was incorporated in 2004 and is headquartered in Petaling Jaya, Malaysia.

Stock analysis

Malaysian Genomics Resource (0155) currently trades at 0.3050 MYR, while our model-based Fair Value estimate is 0.1700 MYR, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 0.1850 MYR per share, and 0 of the 10 models we run sit above the 0.3050 MYR price.

Bear case: the Multiples group reads lowest at 0.0400 MYR, and 10 of the 10 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.0900 MYR (bear) to 0.2600 MYR (bull), the price of 0.3050 MYR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Malaysian Genomics Resource reported revenue of 8.0M MYR in FY2026 versus 28.4M MYR in FY2022, a compound −27.1%/yr. Reported net income was −2.4M MYR in FY2026.

Key figures

Market cap 46.0M MYR (≈ $11.3M) Micro · P/S ratio 4.79 · Net margin −29.7% · Return on equity 0.9% · Return on assets (EBIT) −27.9% (5-year average) · Operating margin 20.7% · Revenue (TTM) 10.1M MYR · Revenue growth (YoY) +42.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 20% below its 52-week high and 79% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −44%, 0155 screens richer than that median.

Fair Value models

Bear 0.0900 MYR Fair Value 0.1700 MYR Bull 0.2600 MYR
Price 0.3050 MYR · Downside -44.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 0.1200 MYR 0.1800 MYR 0.3700 MYR 74
Growth DCF 0.1100 MYR 0.2100 MYR 0.3600 MYR 73
5Y EBITDA Exit 0.0800 MYR 0.1200 MYR 0.2100 MYR 71
All 10 models by family
DCF Models
FCF DCF 0.1200 MYR 0.1800 MYR 0.3700 MYR 74
5Y Revenue Exit 0.0900 MYR 0.1400 MYR 0.2600 MYR 67
5Y EBITDA Exit 0.0800 MYR 0.1200 MYR 0.2100 MYR 71
10Y Revenue Exit 0.1000 MYR 0.2000 MYR 0.2500 MYR 65
10Y EBITDA Exit 0.0900 MYR 0.1700 MYR 0.3000 MYR 63
Multiples
EV/EBITDA 0.0100 MYR 0.0300 MYR 0.0500 MYR 62
EV/Revenue 0.0200 MYR 0.0500 MYR 0.0800 MYR 50
Asset-Based
NCAV (Graham) 0.0300 MYR 0.0400 MYR 0.0500 MYR 55
Growth DCF
Growth DCF 0.1100 MYR 0.2100 MYR 0.3600 MYR 73
Rev-Margin DCF 0.0900 MYR 0.1600 MYR 0.3100 MYR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 69/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 15
How much profit the company makes from its sales and capital
Quality Growth 94
Are margins and returns getting better?
Cashflow 70
Do the profits arrive as real cash?
Financial strength 76
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 51
How calm the share price moves, does not count
Price momentum 85
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 78
Distance to the 52-week high, does not count
New shares 73
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 73/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+45.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.1%
Start year 2021 (pandemic). Over 10 years: −2.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−235.5% (2021) → −9.1% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+24.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about +22.0% a year for the price.

0155 screens overvalued: fair value 44% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Malaysian Genomics Resource with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 69 · Top 25%
Fair Value upside −44.3% · Below median
Profitability
Return on equity (12 months) 0.9% · Below median
Return on assets −12.7% · Bottom 25%
Net margin (12 months) 5.3% · Below median
Operating margin (12 months) 20.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 42.0% · Top 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 2.92× · Pricier than median
P/S (12 months) 4.57× · Pricier than median
Price / free cash flow (fiscal year) 44.6× · Pricier than median
EV/EBITDA 28.1× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 39
PAST (return on equity)4 · sector 15
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs 0155
IQVIA Holdings IQV $271.83 $299.01 +10% vs 0155
Illumina, Inc ILMN $213.13 $234.44 +10% vs 0155
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs 0155
Danaher Corporation DHR $230.25 $209.18 −9% vs 0155
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs 0155
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs 0155
Agilent Technologies, Inc A $174.76 $64.53 −63% vs 0155
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs 0155
Waters Corporation WAT $457.60 $91.26 −80% vs 0155

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Malaysian Genomics Resource: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Malaysian Genomics Resource Fair Value". https://www.fairvalue-calculator.com/stock/0155

Frequently asked questions

Is Malaysian Genomics Resource (0155) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 0.1700 MYR versus a price of 0.3050 MYR, about 44% lower (overvalued).
What is the fair value of 0155?
Our model-based fair value for Malaysian Genomics Resource is 0.1700 MYR (as of Nov 4, 2026), built from audited fundamentals. The current price: 0.3050 MYR.
What is the quality score of 0155?
Malaysian Genomics Resource has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Malaysian Genomics Resource (0155)?
Our model-based price target is the fair value of 0.1700 MYR (as of Nov 4, 2026) from 10 valuation models. Cautious scenario 0.0900 MYR, optimistic scenario 0.2600 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Malaysian Genomics Resource stock forecast for 2026?
Our models put fair value at 0.1700 MYR, about 44% lower versus a price of 0.3050 MYR (overvalued). Cautious scenario 0.0900 MYR, optimistic scenario 0.2600 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Malaysian Genomics Resource (0155)?
Malaysian Genomics Resource reported trailing-twelve-month revenue of about 10.1M MYR (latest available figure, as of Nov 4, 2026).
What growth is priced into Malaysian Genomics Resource (0155)?
For today's price to be fair in a discounted-cash-flow model, Malaysian Genomics Resource would have to grow free cash flow by +24.4 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +35.1 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of 0155 use?
Our models discount Malaysian Genomics Resource at 9.7 %: a base by market capitalisation (nano), damped by beta 0.15, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Malaysian Genomics Resource that is +24.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Malaysian Genomics Resource (0155) delivered so far?
Over the past 5 years revenue at Malaysian Genomics Resource grew +35.1 % a year. The price currently implies free-cash-flow growth of +24.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Malaysian Genomics Resource (0155) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Malaysian Genomics Resource (+24.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Malaysian Genomics Resource (0155)?
The free-cash-flow yield on the price is 2.47 %: that much free cash flow Malaysian Genomics Resource produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Malaysian Genomics Resource (0155)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Malaysian Genomics Resource it is 0.1700 MYR per share (as of Nov 4, 2026), against a price of 0.3050 MYR. It is the blended result of 10 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Malaysian Genomics Resource stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 0155 trades above its calculated fair value: price 0.3050 MYR, fair value 0.1700 MYR, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0155?
No. The price is what the market pays today (0.3050 MYR); the fair value is what the company's own numbers justify (0.1700 MYR). For Malaysian Genomics Resource the two are 0.1350 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Malaysian Genomics Resource worth?
The market values Malaysian Genomics Resource at about 46.0M MYR (market capitalisation, as of Nov 4, 2026). Per share that is 0.3050 MYR; our models calculate a fair value of 0.1700 MYR per share.
What do the bullish and bearish scenarios say about 0155?
Our models span a range for Malaysian Genomics Resource: cautious scenario 0.0900 MYR, base 0.1700 MYR, optimistic 0.2600 MYR per share (as of Nov 4, 2026, price 0.3050 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Malaysian Genomics Resource (0155)?
Balance-sheet figures for Malaysian Genomics Resource (as of Nov 4, 2026): return on equity 0.9%. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is 0155 from its 52-week high?
Malaysian Genomics Resource trades at 0.3050 MYR, about 20% below its 52-week high of 0.3800 MYR and 79% above the low of 0.1700 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1700 MYR is for.
Which stocks are comparable to Malaysian Genomics Resource?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Malaysian Genomics Resource stock attractive at the current price?
The data as of Nov 4, 2026: price 0.3050 MYR, calculated fair value 0.1700 MYR (−44%), Quality Score 69/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0155 calculated?
We run Malaysian Genomics Resource through 10 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 0.1700 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Malaysian Genomics Resource itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Malaysian Genomics Resource (0155)?
The closing price on Nov 6, 2026 was 0.3050 MYR. Our model-based fair value is 0.1700 MYR, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Malaysian Genomics Resource right now?
The price sits above even our optimistic bull case (0.2600 MYR). The favourable scenario is already priced in. The model range is unusually wide (0.0900 MYR to 0.2600 MYR). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Malaysian Genomics Resource

How large is the market capitalisation of Malaysian Genomics Resource (0155)?
The market capitalisation of Malaysian Genomics Resource is 46.0M MYR (≈ $11.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Malaysian Genomics Resource (0155)?
The price-to-sales ratio of Malaysian Genomics Resource is 4.79 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Malaysian Genomics Resource (0155)?
The net margin of Malaysian Genomics Resource is −29.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Malaysian Genomics Resource (0155)?
The return on equity (ROE) of Malaysian Genomics Resource is 0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Malaysian Genomics Resource (0155)?
On an EBIT basis the return on assets of Malaysian Genomics Resource is −27.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Malaysian Genomics Resource (0155)?
The operating margin of Malaysian Genomics Resource is 20.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Malaysian Genomics Resource (0155)?
Revenue at Malaysian Genomics Resource is growing +42.0% versus a year earlier (3y avg −1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Malaysian Genomics Resource (0155) carry?
The net debt of Malaysian Genomics Resource is 6.1M MYR (fiscal year 2019, ≈ 5.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Malaysian Genomics Resource in the live analysis

One click puts Malaysian Genomics Resource on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.